Abstract
Gold(III) complexes have emerged as a versatile and effective class of metal‐based anticancer agents. The development of various types of ligands capable of stabilizing the AuIII cation and preventing its reduction under physiological conditions, such as chelating nitrogen‐donors, dithiocarbamates and C^N cyclometalled ligands, has opened the way for the exploration of their potential intracellular targets and action mechanisms. At the same time, the bioconjugation of AuIII complexes has emerged as a promising strategy for improving the selectivity of this class of compounds for cancer cells over healthy tissues, and recent developments have shown that combining gold complexes with molecular structures that are specifically recognized by the cell can exploit the cell's own transport mechanisms to improve selective metal uptake.
| Original language | English |
|---|---|
| Pages (from-to) | 11840-11851 |
| Number of pages | 12 |
| Journal | Chemistry - A European Journal |
| Volume | 24 |
| Issue number | 46 |
| Early online date | 25 Mar 2018 |
| DOIs | |
| Publication status | Published - 14 Aug 2018 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- antitumor agents
- bioinorganic chemistry
- cancer gold
- pincer ligands
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver